Destiny Pharma PLC - clinical stage biotechnology company - Notes recruitment for Phase 2b clinical study of lead asset XF-73 on track to complete by year-end and report results in early 2021. The phase 2b clinical study is recruiting patients undergoing open heart surgery in US and Europe. Barring any further impact from Covid-19 the study is on plan to complete recruitment by the end of 2020 and report results in the first quarter of 2021.
Chief Executive Neil Clark said: "We are very pleased to report a significant increase in the screening and recruitment of patients in our lead clinical study testing XF-73 as a novel product preventing the incidence of post-surgical infections such as MRSA. In the past few months we have agreed a protocol amendment with the FDA and also reported excellent interim safety data and are looking forward to completing recruitment and reporting the results."
Current stock price: 63.00 pence
Year-to-date change: up 43%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Destiny Pharma. (DEST)